相关实验视频

Updated: Jul 23, 2025

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

干扰素-γ通过PI3K/AKT/mTOR通路促进华堡效应来调节败血症小鼠的免疫抑制

Xu-Zhe Fu¹, Yu Wang²

¹Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang, China.

Molecular medicine (Cambridge, Mass.)

|July 11, 2023

概括

干扰素玛 (IFNγ) 通过增强瓦尔堡效应,一种有氧糖解的形式,逆转败血症诱导的免疫抑制. 这种免疫疗法通过PI3K/Akt/mTOR途径促进葡萄糖代谢和ATP产生,为败血症治疗提供了一个新的治疗点.

科学领域:

免疫学免疫学免疫学
代谢途径代谢途径
败血症的研究研究.

背景情况:

败血症的死亡率是由免疫抑制导致器官功能障碍驱动的.
逆转免疫抑制对于有效的败血症治疗至关重要.
干扰素玛 (IFNγ) 通过恢复单细胞代谢缺陷,显示出血症免疫治疗的潜力,但其机制尚不清楚.

研究的目的:

为了阐明IFNγ在败血症中的免疫治疗机制.
调查华堡效应在IFNγ败血症治疗中的作用.
探索IFNγ如何通过华堡效应和PI3K通路调节免疫抑制.

主要方法:

使用树突细胞 (DC) 建立了体内 (切卡结合穿孔) 和体内 (脂多糖刺激) 败血症模型.
利用华堡效应抑制剂 (2-DG) 和PI3K通路抑制剂 (LY294002) 来研究IFNγ的机制.
分析了细胞因子分泌,DC亡,调节性T细胞的形成,以及关键蛋白的表达 (例如CD86,HLA-DR,BCL-2,Bax,PDH,LDH,Glut1,Glut4,PI3K,Akt,mTOR,HIF-1α,PDK1).

主要成果:

IFNγ增强了细胞因子分泌,增加了CD86和HLA-DR在DC上的表达,并减少了DC的亡.
IFNγ治疗消除了CLP诱导的调节性T细胞,并减少了DCs中的自细胞形成.
IFNγ通过上调葡萄糖消耗,乳酸和ATP生产来促进华堡效应,同时抑制相关蛋白质;这种效应被2-DG阻止.
IFNγ激活了PI3K/Akt/mTOR通路,由蛋白质表达的增加证明,该蛋白质表达被2-DG和LY294002抑制,而LY294002也阻断了IFNγ的治疗作用.

结论:

IFNγ通过PI3K/Akt/mTOR通路促进华堡效应来逆转败血症诱导的免疫抑制.
这项研究阐明了IFNγ在败血症中的免疫治疗机制.
这些发现为败血症治疗提供了一个新的治疗点.

关键词:

免疫抑制是一种免疫抑制.干扰素 - 玛的干扰素.代谢过程中的代谢.败血症这是一种败血症.华堡效应是什么? 华堡效应

更多相关视频

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection

Published on: July 16, 2019

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Published on: March 2, 2014

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...